Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Jumpcode Genomics Inc. manages 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. This activity represents the company's current efforts to secure intellectual property for its genomic innovations.
The portfolio is distributed among 3 distinct examiners and 3 distinct art units. This distribution shows that each of the 3 pending actions is being reviewed in a different technical category by a different examiner at the patent office.
Catherine S Hibbert is the busiest examiner, currently handling 1 pending office action. This examiner manages 1 of the 3 total pending actions, reflecting a balanced distribution of the workload across the portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HIBBERT, CATHERINE S | 1 | 58.8% | +48.6% |
| BERTAGNA, ANGELA MARIE | 1 | 44.7% | +46.3% |
| GUSSOW, ANNE | 1 | 57.9% | +43.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18163196 | CAPTURE OF NUCLEIC ACIDS USING A NUCLEIC ACID-GUIDED NUCLEASE-BASED SYSTEM | BERTAGNA, ANGELA MARIE | — |
| 17761866 | METHOD AND SYSTEM FOR TARGETED NUCLEIC ACID SEQUENCING | GUSSOW, ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18615960 | COMPOSITIONS AND METHODS FOR TARGETED DEPLETION, ENRICHMENT, AND PARTITIONING OF NUCLEIC ACIDS USING CRISPR/CAS SYSTEM PROTEINS | HIBBERT, CATHERINE S | — |
| 18163196 | CAPTURE OF NUCLEIC ACIDS USING A NUCLEIC ACID-GUIDED NUCLEASE-BASED SYSTEM | BERTAGNA, ANGELA MARIE | — |
| 17761866 | METHOD AND SYSTEM FOR TARGETED NUCLEIC ACID SEQUENCING | GUSSOW, ANNE | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| 1681 | 1 |
| 1600 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18615960 | COMPOSITIONS AND METHODS FOR TARGETED DEPLETION, ENRICHMENT, AND PARTITIONING OF NUCLEIC ACIDS USING CRISPR/CAS SYSTEM PROTEINS | HIBBERT, CATHERINE S | 1658 | §103§112DP | Non-Final OA | — | Pending | Mar 25, 2024 |
| 18163196 | CAPTURE OF NUCLEIC ACIDS USING A NUCLEIC ACID-GUIDED NUCLEASE-BASED SYSTEM | BERTAGNA, ANGELA MARIE | 1681 | §103§112 | Non-Final OA | — | Pending | Feb 01, 2023 |
| 17761866 | METHOD AND SYSTEM FOR TARGETED NUCLEIC ACID SEQUENCING | GUSSOW, ANNE | 1600 | §102§103§112 | Final Rejection | — | Pending | Mar 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJumpcode Genomics Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Catherine S Hibbert has the most, with 1 of Jumpcode Genomics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
